Yuguo Li1,2, Yuan Qiao3, Hanwei Chen2,4, Renyuan Bai5, Verena Staedtke5, Zheng Han1,2, Jiadi Xu1,2, Kannie W Y Chan1,2,6, Nirbhay Yadav1,2, Jeff W M Bulte1,2,7, Shibin Zhou3, Peter C M van Zijl1,2, Guanshu Liu1,2. 1. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA. 2. Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of Radiology, Panyu Central Hospital, Guangzhou, China. 5. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 6. Department of Mechanical and Biomedical Engineering, City University of Hong Kong, Hong Kong, China. 7. Cellular Imaging Section and Vascular Biology Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE: To investigate the use of natural dextrans as nano-sized chemical exchange saturation transfer (CEST) MRI probes for characterizing size-dependent tumor vascular permeability. METHODS: Dextrans of different molecular weight (10, 70, 150, and 2000 kD) were characterized for their CEST contrast. Mice (N = 5) bearing CT26 subcutaneous colon tumors were injected intravenously with 10 kD (D10, 6 nm) and 70 kD (D70, 12 nm) dextran at a dose of 375 mg/kg. The CEST-MRI signal in the tumors was assessed before and approximately 40 min after each injection using a dynamic CEST imaging scheme. RESULTS: All dextrans of different molecular weights have a strong CEST signal with an apparent maximum of approximately 0.9 ppm. The detectability and effects of pH and saturation conditions (B1 and Tsat ) were investigated. When applied to CT26 tumors, the injection of D10 could produce a significant "dexCEST" enhancement in the majority of the tumor area, whereas the injection of D70 only resulted in an increase in the tumor periphery. Quantitative analysis revealed the differential permeability of CT26 tumors to different size particles, which was validated by fluorescence imaging and immunohistochemistry. CONCLUSIONS: As a first application, we used 10- and 70-kD dextrans to visualize the spatially variable, size-dependent permeability in the tumor, indicating that nano-sized dextrans can be used for characterizing tumor vascular permeability with dexCEST MRI and, potentially, for developing dextran-based theranostic drug delivery systems. Magn Reson Med 79:1001-1009, 2018.
PURPOSE: To investigate the use of natural dextrans as nano-sized chemical exchange saturation transfer (CEST) MRI probes for characterizing size-dependent tumor vascular permeability. METHODS:Dextrans of different molecular weight (10, 70, 150, and 2000 kD) were characterized for their CEST contrast. Mice (N = 5) bearing CT26 subcutaneous colon tumors were injected intravenously with 10 kD (D10, 6 nm) and 70 kD (D70, 12 nm) dextran at a dose of 375 mg/kg. The CEST-MRI signal in the tumors was assessed before and approximately 40 min after each injection using a dynamic CEST imaging scheme. RESULTS: All dextrans of different molecular weights have a strong CEST signal with an apparent maximum of approximately 0.9 ppm. The detectability and effects of pH and saturation conditions (B1 and Tsat ) were investigated. When applied to CT26tumors, the injection of D10 could produce a significant "dexCEST" enhancement in the majority of the tumor area, whereas the injection of D70 only resulted in an increase in the tumor periphery. Quantitative analysis revealed the differential permeability of CT26tumors to different size particles, which was validated by fluorescence imaging and immunohistochemistry. CONCLUSIONS: As a first application, we used 10- and 70-kD dextrans to visualize the spatially variable, size-dependent permeability in the tumor, indicating that nano-sized dextrans can be used for characterizing tumor vascular permeability with dexCEST MRI and, potentially, for developing dextran-based theranostic drug delivery systems. Magn Reson Med 79:1001-1009, 2018.
Authors: Guanshu Liu; Assaf A Gilad; Jeff W M Bulte; Peter C M van Zijl; Michael T McMahon Journal: Contrast Media Mol Imaging Date: 2010 May-Jun Impact factor: 3.161
Authors: Kannie W Y Chan; Michael T McMahon; Yoshinori Kato; Guanshu Liu; Jeff W M Bulte; Zaver M Bhujwalla; Dmitri Artemov; Peter C M van Zijl Journal: Magn Reson Med Date: 2012-10-16 Impact factor: 4.668
Authors: Nishant Agrawal; Chetan Bettegowda; Ian Cheong; Jean-Francois Geschwind; Charles G Drake; Edward L Hipkiss; Mitsuaki Tatsumi; Long H Dang; Luis A Diaz; Martin Pomper; Mohammad Abusedera; Richard L Wahl; Kenneth W Kinzler; Shibin Zhou; David L Huso; Bert Vogelstein Journal: Proc Natl Acad Sci U S A Date: 2004-10-07 Impact factor: 11.205
Authors: Zheng Han; Chuheng Chen; Xiang Xu; Renyuan Bai; Verena Staedtke; Jianpan Huang; Kannie W Y Chan; Jiadi Xu; David O Kamson; Zhibo Wen; Linda Knutsson; Peter C M van Zijl; Guanshu Liu Journal: NMR Biomed Date: 2021-11-15 Impact factor: 4.044
Authors: Hanwei Chen; Dexiang Liu; Yuguo Li; Xiang Xu; Jiadi Xu; Nirbhay N Yadav; Shibin Zhou; Peter C M van Zijl; Guanshu Liu Journal: Magn Reson Med Date: 2019-05-20 Impact factor: 3.737
Authors: Puneet Bagga; Neil Wilson; Laurie Rich; Francesco M Marincola; Mitchell D Schnall; Hari Hariharan; Mohammad Haris; Ravinder Reddy Journal: Sci Rep Date: 2019-07-31 Impact factor: 4.379